BioLineRx Ltd. BLRX
1.49 USD -0.03 (-1.97%)
At closeNov 11, 2026, 4:00 PM EST
1.51 +0.02 +1.34%
After hours · Nov 11, 4:00 PM ET
1.48 Day range 1.63
1.49 52-week range 3.78
- YTD
- -46.21%
- 1 year
- -55.39%
News
benzinga.com BioLineRx And Hemispherian Present Data At ESMO 2026 Demonstrating Synergy Between GLIX1 And Multiple PARPi In Homologous Recombination-Proficient Ovarian Cancer Cell Lines And In In Vivo Patient-Derived Xenograft Model GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand…
prnewswire.com BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand…
benzinga.com BioLineRx Announces That Two Abstracts Featuring GLIX1 Will Be Presented At The Society For Neuro-Oncology Annual Meeting, November 12-15 The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients…
prnewswire.com BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
benzinga.com BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026 BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology…
prnewswire.com BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
seekingalpha.com BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
benzinga.com BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent. This is a 3.29 percent decrease over sales of…
prnewswire.com BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
benzinga.com BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced…
prnewswire.com BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies…
prnewswire.com BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd.- benzinga.com BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell LinesPresentation #: 1435ePPresentation type:…
prnewswire.com BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Innovative Eyewear (NASDAQ:LUCY)…
- benzinga.com BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug…
prnewswire.com BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
seekingalpha.com BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
benzinga.com BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of…
prnewswire.com BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple…- benzinga.com BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual Meeting BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology…
prnewswire.com BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and…
prnewswire.com BioLineRx to Report First Quarter 2026 Results on May 27, 2026 Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
benzinga.com BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.
benzinga.com BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally…
prnewswire.com BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr.…
prnewswire.com BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the…
businesswire.com Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical…- benzinga.com BioLineRx Launches First Human Trial For Brain Cancer Drug BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a…
prnewswire.com BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple…- benzinga.com BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent. The company reported quarterly sales of $194.000…
seekingalpha.com BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript- benzinga.com BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent. This is a 98.35 percent decrease over sales…
benzinga.com Earnings Scheduled For March 23, 2026 
prnewswire.com BioLineRx Reports 2025 Financial Results and Provides Corporate Update - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more…
defenseworld.net BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per…
benzinga.com Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees https://ir.biolinerx.com/static-files/e6f7cf56-4605-44e6-8ed9-f0738b67b983
- benzinga.com BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07)…
- benzinga.com Earnings Scheduled For November 24, 2025
benzinga.com BioLine Rx's Earnings: A Preview